Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole in children with CNS disorders
NCT03292848Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brexpiprazole orally disintegrating tablet in attention deficit hyperactivity disorder (ADHD), Autism Spectrum Disorder (ASD), bipolar I disorder and 3 more, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Oct 2017; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
attention deficit hyperactivity disorder (ADHD)Autism Spectrum Disorder (ASD)bipolar I disorderconduct disorder (CD)oppositional defiant disorder (ODD)
Beyond the preview
Go deeper on NCT03292848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292848.